EA200500377A1 - Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf) - Google Patents

Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)

Info

Publication number
EA200500377A1
EA200500377A1 EA200500377A EA200500377A EA200500377A1 EA 200500377 A1 EA200500377 A1 EA 200500377A1 EA 200500377 A EA200500377 A EA 200500377A EA 200500377 A EA200500377 A EA 200500377A EA 200500377 A1 EA200500377 A1 EA 200500377A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tgf
growth factor
inhibitors
transforming growth
pyrazol derivatives
Prior art date
Application number
EA200500377A
Other languages
English (en)
Inventor
Майкл Джон Манчхоф
Лаура Кук Блюмберг
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200500377A1 publication Critical patent/EA200500377A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Описаны новые пиразольные производные формулы (Ia), промежуточные соединения для их получения, содержащие их фармацевтические композиции и их медицинское применение. Соединения настоящего изобретения являются эффективными ингибиторами сигнального пути трансформирующего β-фактора роста (TGF). Они полезны при лечении разнообразных болезненных состояний, связанных с TGF, включая, например, рак и фиброзные заболевания.Отчет о международном поиске был опубликован 2004.07.01.
EA200500377A 2002-09-18 2003-09-08 Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf) EA200500377A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41214602P 2002-09-18 2002-09-18
US48454303P 2003-07-02 2003-07-02
PCT/IB2003/003933 WO2004026306A2 (en) 2002-09-18 2003-09-08 Pyrazole derivatives as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number Publication Date
EA200500377A1 true EA200500377A1 (ru) 2005-08-25

Family

ID=32033585

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500377A EA200500377A1 (ru) 2002-09-18 2003-09-08 Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)

Country Status (27)

Country Link
US (4) US6958354B2 (ru)
EP (2) EP2165708A3 (ru)
JP (1) JP4519657B2 (ru)
KR (1) KR20050044807A (ru)
CN (1) CN1681501A (ru)
AP (1) AP2005003263A0 (ru)
AR (1) AR041272A1 (ru)
AT (1) ATE450258T1 (ru)
AU (1) AU2003259475A1 (ru)
BR (1) BR0314302A (ru)
CA (1) CA2496295C (ru)
CO (1) CO5550456A2 (ru)
DE (1) DE60330362D1 (ru)
EA (1) EA200500377A1 (ru)
EC (1) ECSP055679A (ru)
ES (1) ES2335099T3 (ru)
HR (1) HRP20050247A2 (ru)
IS (1) IS7698A (ru)
MA (1) MA27440A1 (ru)
MX (1) MXPA05002376A (ru)
NO (1) NO20050838L (ru)
OA (1) OA12929A (ru)
PA (1) PA8583201A1 (ru)
PE (1) PE20040988A1 (ru)
PL (1) PL375979A1 (ru)
UY (1) UY27985A1 (ru)
WO (1) WO2004026306A2 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2737737C2 (ru) * 2016-06-13 2020-12-02 Джинфлит Терапьютикс (Шанхай) Инк. АЛЬФА- И БЕТА-НЕНАСЫЩЕННОЕ АМИДНОЕ СОЕДИНЕНИЕ - ПРОИЗВОДНОЕ БЕНЗОТРИАЗОЛА, ПРИМЕНЯЕМОЕ В КАЧЕСТВЕ ИНГИБИТОРА TGF-βRI
RU2750702C1 (ru) * 2017-12-13 2021-07-01 Джинфлит Терапьютикс (Шанхай) Инк. КРИСТАЛЛИЧЕСКАЯ ФОРМА И СОЛЕВАЯ ФОРМА ИНГИБИТОРА TGF-βRI И СПОСОБ ИХ ПОЛУЧЕНИЯ

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1681805A (zh) * 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物
JP4519657B2 (ja) * 2002-09-18 2010-08-04 ファイザー・プロダクツ・インク 形質転換成長因子（ｔｇｆ）阻害剤としての新規なピラゾ−ル化合物
DE60327443D1 (de) 2002-09-18 2009-06-10 Pfizer Prod Inc Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf)
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
US20080171755A1 (en) * 2004-08-31 2008-07-17 Wen-Cherng Lee Pyrimidinylpyrazoles as Tgf-Beta Inhibitors
EP1798229A4 (en) * 2004-09-07 2009-07-29 Sankyo Co SUBSTITUTED BIPHENYL DERIVATIVE
JP2008516962A (ja) * 2004-10-15 2008-05-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管傷害を治療する方法
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
WO2007070866A2 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
UA92670C2 (ru) 2006-10-31 2010-11-25 Пфайзер Продактс Инк. Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
AU2008281543A1 (en) * 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as Raf inhibitors
ES2813875T3 (es) 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso
WO2016160881A1 (en) 2015-04-01 2016-10-06 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP3429603B1 (en) 2016-03-15 2021-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US11266647B2 (en) * 2016-10-26 2022-03-08 Icahn School Of Medicine At Mount Sinai Method for increasing cell proliferation in pancreatic beta cells, treatment method, and composition
EP3539957A4 (en) * 2016-11-14 2020-05-13 Jiangsu Hengrui Medicine Co., Ltd. 3,4-BIPYRIDYL-PYRAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR AND MEDICAL USE THEREOF
CA3084581A1 (en) 2017-11-20 2019-05-23 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
AU2019205944A1 (en) 2018-01-05 2020-07-09 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
TW202012390A (zh) * 2018-06-29 2020-04-01 日商日本歐愛特農業科技股份有限公司 新穎之經取代吡唑衍生物
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3894401A2 (en) 2018-12-11 2021-10-20 Theravance Biopharma R&D IP, LLC Naphthyridine and quinoline derivatives useful as alk5 inhibitors
CN110467601B (zh) * 2019-08-29 2021-07-02 杭州市西溪医院 一种吡唑联吡啶酮类化合物、中间体及其制备方法及应用
IL293084A (en) 2019-11-22 2022-07-01 Theravance Biopharma R& D Ip Llc 5,1-Converted naphthyridines or quinolines as alk5 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (ru) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4925857A (en) * 1989-03-22 1990-05-15 Sterling Drug Inc. Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents
JP3734180B2 (ja) * 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
BR9809451A (pt) 1997-05-22 2000-06-20 Searle & Co Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
WO2000061576A1 (en) 1999-04-09 2000-10-19 Smithkline Beecham Corporation Triarylimidazoles
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
WO2002040468A1 (en) 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
JP2004521901A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
US20040087623A1 (en) * 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
MXPA03008142A (es) 2001-03-09 2003-12-12 Pfizer Prod Inc Nuevos compuestos antiinflamatorios de bencimidazol.
EP1382603B1 (en) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2005539000A (ja) 2002-07-31 2005-12-22 スミスクライン・ビーチャム・コーポレイション Ａｌｋ５阻害剤としての２−フェニルピリジン−４−イル誘導体
EA200500286A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
AP2005003260A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel triazole compounds as transforming growth factor (TGF) inhibitors.
CN1681805A (zh) 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物
JP4519657B2 (ja) * 2002-09-18 2010-08-04 ファイザー・プロダクツ・インク 形質転換成長因子（ｔｇｆ）阻害剤としての新規なピラゾ−ル化合物
DE60327443D1 (de) 2002-09-18 2009-06-10 Pfizer Prod Inc Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf)
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2737737C2 (ru) * 2016-06-13 2020-12-02 Джинфлит Терапьютикс (Шанхай) Инк. АЛЬФА- И БЕТА-НЕНАСЫЩЕННОЕ АМИДНОЕ СОЕДИНЕНИЕ - ПРОИЗВОДНОЕ БЕНЗОТРИАЗОЛА, ПРИМЕНЯЕМОЕ В КАЧЕСТВЕ ИНГИБИТОРА TGF-βRI
RU2750702C1 (ru) * 2017-12-13 2021-07-01 Джинфлит Терапьютикс (Шанхай) Инк. КРИСТАЛЛИЧЕСКАЯ ФОРМА И СОЛЕВАЯ ФОРМА ИНГИБИТОРА TGF-βRI И СПОСОБ ИХ ПОЛУЧЕНИЯ
US11236112B2 (en) 2017-12-13 2022-02-01 Genfleet Therapeutics (Shanghai) Inc. Crystal form and salt form of TGF-βRI inhibitor and preparation method therefor

Also Published As

Publication number Publication date
BR0314302A (pt) 2005-07-05
DE60330362D1 (de) 2010-01-14
ES2335099T3 (es) 2010-03-22
AR041272A1 (es) 2005-05-11
ECSP055679A (es) 2005-05-30
AU2003259475A1 (en) 2004-04-08
PL375979A1 (en) 2005-12-12
US7638537B2 (en) 2009-12-29
KR20050044807A (ko) 2005-05-12
CA2496295A1 (en) 2004-04-01
HRP20050247A2 (en) 2005-10-31
EP1542684B1 (en) 2009-12-02
ATE450258T1 (de) 2009-12-15
AP2005003263A0 (en) 2005-03-31
US6958354B2 (en) 2005-10-25
IS7698A (is) 2005-02-17
OA12929A (en) 2006-10-13
CO5550456A2 (es) 2005-08-31
US20100056571A1 (en) 2010-03-04
WO2004026306A3 (en) 2004-07-01
US20040116474A1 (en) 2004-06-17
EP1542684A2 (en) 2005-06-22
UY27985A1 (es) 2004-04-30
JP4519657B2 (ja) 2010-08-04
US20070117850A1 (en) 2007-05-24
JP2006507353A (ja) 2006-03-02
US20060025451A1 (en) 2006-02-02
CA2496295C (en) 2010-11-23
EP2165708A2 (en) 2010-03-24
NO20050838L (no) 2005-05-18
PE20040988A1 (es) 2004-12-25
CN1681501A (zh) 2005-10-12
MXPA05002376A (es) 2005-05-23
US7151110B2 (en) 2006-12-19
PA8583201A1 (es) 2004-04-23
WO2004026306A2 (en) 2004-04-01
MA27440A1 (fr) 2005-07-01
EP2165708A3 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
EA200500286A1 (ru) Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
EA200500354A1 (ru) Новые оксазольные и тиазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
EA200500378A1 (ru) Новые соединения имидазола в качестве ингибиторов трансформирующего фактора роста (tgf)
ATE402929T1 (de) Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
EA200500376A1 (ru) Триазольные производные в качестве ингибиторов трансформирующего фактора роста (tgf)
TW200504069A (en) Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
EA200400432A1 (ru) Производные мочевины
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
SE0103836D0 (sv) Novel compounds
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
SE9903997D0 (sv) New compounds
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
SE9903894D0 (sv) Novel compounds
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CY1106711T1 (el) Υποκατεστημενα παραγωγα προπανο-1,3-διαμινης και η φαρμακευτικη χρηση τους
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
EE05329B1 (et) GlyT-1 inhibiitorid, neid sisaldavad kompositsioonid, nende kasutamine ja nende valmistamise vahehendid
SE0301698D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EA200500235A1 (ru) Новые производные пиперазинона для лечения нарушений, связанных с 5-ht-рецептором
EA200601270A1 (ru) Новые индено[2,1-a]индены и изоиндоло[2,1-a]индолы